Ariad Pharmaceuticals Inc fka ARIA

[piece o mind]

Well, considering biotech is a risky investment, even for insiders, these purchases are telling. Success for all indications is a ways off. Also, even after months/years of research, success is still not a given, with the fda having the final say.
These monthly share purchases could indicate an insider knowledge of not wanting to miss out on a more realistic opportunity. An opportunity that the company may now be considering and reveal 1st half of next year?
Financial logic should prevail for ariad